These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 24209829

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.
    Cochrane Database Syst Rev; 2014 May 22; 2014(5):CD004772. PubMed ID: 24852077
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Early antiretroviral therapy and mortality among HIV-infected infants.
    Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA, CHER Study Team.
    N Engl J Med; 2008 Nov 20; 359(21):2233-44. PubMed ID: 19020325
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D.
    Cochrane Database Syst Rev; 2012 Jul 11; (7):CD004772. PubMed ID: 22786492
    [Abstract] [Full Text] [Related]

  • 7. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E, MOBIDIP study group.
    Lancet HIV; 2017 Sep 11; 4(9):e384-e392. PubMed ID: 28566227
    [Abstract] [Full Text] [Related]

  • 8. Cognitive outcomes at ages seven and nine years in South African children from the children with HIV early antiretroviral (CHER) trial: a longitudinal investigation.
    van Wyhe KS, Laughton B, Cotton MF, Meintjes EM, van der Kouwe AJ, Boivin MJ, Kidd M, Thomas KG.
    J Int AIDS Soc; 2021 Jul 11; 24(7):e25734. PubMed ID: 34259393
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
    Kunisaki KM, Niewoehner DE, Collins G, Aagaard B, Atako NB, Bakowska E, Clarke A, Corbelli GM, Ekong E, Emery S, Finley EB, Florence E, Infante RM, Kityo CM, Madero JS, Nixon DE, Tedaldi E, Vestbo J, Wood R, Connett JE, INSIGHT START Pulmonary Substudy Group.
    Lancet Respir Med; 2016 Dec 11; 4(12):980-989. PubMed ID: 27773665
    [Abstract] [Full Text] [Related]

  • 12. Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.
    Siegfried N, Davies MA, Penazzato M, Muhe LM, Egger M.
    Cochrane Database Syst Rev; 2013 Oct 10; 10(10):CD010309. PubMed ID: 24114324
    [Abstract] [Full Text] [Related]

  • 13. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
    O'Connor J, Vjecha MJ, Phillips AN, Angus B, Cooper D, Grinsztejn B, Lopardo G, Das S, Wood R, Wilkin A, Klinker H, Kantipong P, Klingman KL, Jilich D, Herieka E, Denning E, Abubakar I, Gordin F, Lundgren JD, INSIGHT START study group.
    Lancet HIV; 2017 Mar 10; 4(3):e105-e112. PubMed ID: 28063815
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.
    Molina JM, Grund B, Gordin F, Williams I, Schechter M, Losso M, Law M, Ekong E, Mwelase N, Skoutelis A, Wiselka MJ, Vandekerckhove L, Benfield T, Munroe D, Lundgren JD, Neaton JD, INSIGHT START study group.
    Lancet HIV; 2018 Apr 10; 5(4):e172-e180. PubMed ID: 29352723
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.